当前位置: 首页 JCRQ3 期刊介绍(非官网)
Faseb Bioadvances

Faseb Bioadvances

SCIE

国际简称:FASEB BIOADV  参考译名:生物进展

  • 中科院分区

    3区

  • CiteScore分区

    Q2

  • JCR分区

    Q3

基本信息:
ISSN:2573-9832
是否OA:未开放
是否预警:否
TOP期刊:否
出版信息:
出版地区:United States
出版商:Wiley
出版语言:English
研究方向:Multiple
评价信息:
影响因子:2.4
CiteScore指数:3.5
SJR指数:0.776
SNIP指数:0.653
发文数据:
Gold OA文章占比:100.00%
研究类文章占比:84.21%
年发文量:76
自引率:0.0370...
开源占比:0.6923
出版撤稿占比:
出版国人文章占比:0
OA被引用占比:
英文简介 期刊介绍 CiteScore数据 中科院SCI分区 JCR分区 发文数据 常见问题

英文简介Faseb Bioadvances期刊介绍

Faseb Bioadvancements aims to provide a platform for the global bioscience community to publish high-quality research papers. This journal focuses on publishing interdisciplinary biomedical research, regardless of the impact of the research results. As long as the research design and execution are appropriate, it can be considered acceptable. In addition to newly discovered reports, it also welcomes the publication of confirmatory studies and reports based on negative findings.

One of the characteristics of this journal is its emphasis on original research, encouraging scientists to submit their research results, whether it is basic research or translational research. In addition, the magazine also considers publishing opinion articles, opinion fragments, and reports, which cover various aspects of biomedical and biological research, including methodology, education, and history of science. The editorial department of the magazine is composed of a group of well-known senior reviewers who are not only responsible for reviewing articles, but also encourage their colleagues to submit articles to the journal and serve as journal ambassadors. The journal has also launched special topic and small review programs to focus on topics of interest to the scientific community.

期刊简介Faseb Bioadvances期刊介绍

《Faseb Bioadvances》是一本生物优秀杂志。致力于发表原创科学研究结果,并为生物各个领域的原创研究提供一个展示平台,以促进生物领域的的进步。该刊鼓励先进的、清晰的阐述,从广泛的视角提供当前感兴趣的研究主题的新见解,或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道生物领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单,目前已被权威数据库SCIE收录,得到了广泛的认可。

该期刊投稿重要关注点:

Cite Score数据(2026年6月最新版)Faseb Bioadvances Cite Score数据

  • CiteScore:3.5
  • SJR:0.776
  • SNIP:0.653
学科类别 分区 排名 百分位
大类:Biochemistry, Genetics and Molecular Biology 小类:Biochemistry, Genetics and Molecular Biology (miscellaneous) Q2 65 / 144

55%

大类:Biochemistry, Genetics and Molecular Biology 小类:Physiology Q3 128 / 196

34%

大类:Biochemistry, Genetics and Molecular Biology 小类:Cancer Research Q3 170 / 233

27%

大类:Biochemistry, Genetics and Molecular Biology 小类:Molecular Medicine Q3 131 / 179

27%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础,针对的是前四年发表的论文的引文。CiteScore的意义在于,它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法,而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Faseb Bioadvances 中科院分区

《新锐期刊分区表》(2026年3月发布) 综述期刊:否 Top期刊:否
大类学科 分区 小类学科 分区
生物学 3区 BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学 CELL BIOLOGY 细胞生物学 4区 4区
期刊分区表(2025年3月升级版) 综述期刊:否 Top期刊:否
大类学科 分区 小类学科 分区
生物学 4区 BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学 CELL BIOLOGY 细胞生物学 4区 4区

中科院分区表 是以客观数据为基础,运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据,得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次,类似于“优、良、及格”等。最开始,这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Faseb Bioadvances JCR分区

2025-2026年最新版
按JCI指标学科分区 收录子集 分区 排名 百分位
学科:BIOCHEMISTRY & MOLECULAR BIOLOGY ESCI Q3 244 / 328

25.8

学科:CELL BIOLOGY ESCI Q4 161 / 207

22.5

学科:BIOCHEMISTRY & MOLECULAR BIOLOGY ESCI Q4 269 / 328

18.14

学科:CELL BIOLOGY ESCI Q4 166 / 207

20.05

2023-2024年最新版
按JCI指标学科分区 收录子集 分区 排名 百分位
学科:BIOCHEMISTRY & MOLECULAR BIOLOGY ESCI Q3 216 / 313

31.2

学科:CELL BIOLOGY ESCI Q3 148 / 205

28

学科:BIOCHEMISTRY & MOLECULAR BIOLOGY ESCI Q4 260 / 313

17.09

学科:CELL BIOLOGY ESCI Q4 166 / 205

19.27

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异,此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此,JCR将期刊按照学科门类和影响因子分为不同的分区,这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

本刊中国学者近年发表论文

  • 1、Network Analysis Identifies Microsomal Glutathione S-Transferase as a Potential Regulator of Oxidative Stress and Proteasome Dysfunction in Human Osteoarthritic Menisc

    Author: Wu, Xinjie; Hamzatova, Amina; Aulin, Cecilia; Sun, Wei; Struglics, Andre; Hart, David A.; Ackermann, Paul W.; Ahmed, Aisha S

    Journal: FASEB BIOADVANCES. 2026; Vol. 8, Issue 5, pp. -. DOI: 10.1096/fba.2025-00302

  • 2、Temperature-Gradient Transcriptomic Atlas Reveals the PPAR Signaling Pathway Dysfunction in Heat Stroke Induced Liver Injur

    Author: Zhu, Ying; Liu, Wanlin; Yang, Chunyuan; Ma, Teng; Han, Mingfei; Zhang, Jinxu; Zhu, Yunping; Ma, Jie

    Journal: FASEB BIOADVANCES. 2026; Vol. 8, Issue 3, pp. -. DOI: 10.1096/fba.2025-00308

  • 3、Circadian Reprogramming of Protein Homeostasis and Glycolipid Metabolism in Diabetic Nephropath

    Author: Li, Xiao-Qian; Cheng, Lei; Chen, Tian-Fen; Ma, Yi-Nuo; Wang, Lu-Yao; Li, Xiao-Hui; Fu, Ting-Yu; Xiao, Jing; Zhao, Zhan-Zheng

    Journal: FASEB BIOADVANCES. 2026; Vol. 8, Issue 2, pp. -. DOI: 10.1096/fba.2025-00305

  • 4、Keratinocyte-Associated Biomarkers Reveal Pathogenic Mechanisms in Acn

    Author: Cai, Sini; Lin, Yinjing; Xie, Heng; Ao, Xian; Liu, Qiwei; Huang, Lining

    Journal: FASEB BIOADVANCES. 2026; Vol. 8, Issue 2, pp. -. DOI: 10.1096/fba.2025-00255

  • 5、The Hill-Type Equation Reveals the Regulatory Principle of Target Protein Expression Led by p53 Pulsin

    Author: Shi, Xiaomin

    Journal: FASEB BIOADVANCES. 2025; Vol. , Issue , pp. -. DOI: 10.1096/fba.2024-00220

  • 6、Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicin

    Author: Wu, Yu; Deng, Yuru; Angelov, Borislav; Angelova, Angelina

    Journal: FASEB BIOADVANCES. 2025; Vol. , Issue , pp. -. DOI: 10.1096/fba.2025-00010

  • 7、Induction of Peroxisomal β-Oxidation as a Critical Mechanism for Ethanol-Induced Hepatic Triglyceride Accumulatio

    Author: Zhang, Yida; Zhang, Wei; Li, Yicong; Yao, Haoya; Wang, Yaoqing; Zhang, Xiao; Zeng, Jia

    Journal: FASEB BIOADVANCES. 2025; Vol. , Issue , pp. -. DOI: 10.1096/fba.2024-00211

  • 8、NPC1L1 Drives Osteoporosis by Activating the C/EBPα/Cyp27a1/27-Hydroxycholesterol Axis: A Novel Therapeutic Target for Bone Los

    Author: Li, Bohao; Zhou, Wuling; Yu, Yueming; Chen, Boyu; Lv, Zhicheng; Zhang, Jiarui; Zhang, Tieqi; Sun, Shiwei; Zhou, Lei; Wang, Minghai

    Journal: FASEB BIOADVANCES. 2025; Vol. , Issue , pp. -. DOI: 10.1096/fba.2025-00044

投稿常见问题